文献速递甲状腺疾病

良性甲状腺结节的微创治疗:短期结局的网络Meta分析

Minimally Invasive Treatments of Benign Thyroid Nodules: A Network Meta-Analysis of Short-Term Outcomes.
PubMed 文献 · Thyroid · 2023-07-10

本研究通过系统综述与贝叶斯网络Meta分析,纳入16项研究共4112例患者,比较射频消融、激光消融、微波消融、高强度聚焦超声与常规手术对良性甲状腺结节短期结局的疗效与安全性。结果显示各干预在体积缩小率、症状评分与美容评分上无显著差异;消融类技术在嗓音并发症、喉返神经损伤及甲状腺功能减退风险上低于常规手术,其中射频消融安全性排名最高。

要点

  • 各干预在体积缩小率、症状评分与美容评分上均无显著差异。
  • 射频消融、激光消融与微波消融的术后嗓音并发症风险低于常规手术。
  • 射频消融与微波消融的暂时性喉返神经损伤及甲状腺功能减退风险低于常规手术。

核心结论

  • 射频消融、激光消融、微波消融、高强度聚焦超声与常规手术在体积缩小率、症状评分与美容评分上均无显著差异。
  • 消融类技术在嗓音并发症、喉返神经损伤和甲状腺功能减退风险上低于常规手术,其中射频消融安全性排名最高。
  • 作者指出长期数据与高质量随机对照试验仍匮乏。

研究设计与样本

  • 系统综述与贝叶斯网络Meta分析(PROSPERO CRD42022367680)。
  • 纳入16项研究,包括3项随机对照试验和13项比较性病例系列。
  • 共纳入4112例患者,平均随访11.9个月。
  • 干预包括射频消融、激光消融、微波消融、高强度聚焦超声与常规手术。

主要发现

  • 主要终点体积缩小率、症状评分与美容评分在各干预间均无显著差异。
  • 累积排序曲线下面积(SUCRA)显示常规手术(98.49)、微波消融(57.0)和激光消融(51.58)最可能获得最大体积缩小率、症状与美容评分改善。
  • 与常规手术相比,射频消融(RR 0.19,95%CI 0.06至0.48)、激光消融(RR 0.23,95%CI 0.06至0.79)和微波消融(RR 0.25,95%CI 0.09至0.60)与术后嗓音并发症风险降低相关,射频消融安全性SUCRA最高(61.62)。
  • 与常规手术相比,射频消融(RR 0.05,95%CI 0.00至0.40)和微波消融(RR 0.16,95%CI 0.02至0.73)与暂时性喉返神经损伤风险降低相关。
  • 与常规手术相比,射频消融(RR 0.00,95%CI 0.00至0.00)和微波消融(RR 0.00,95%CI 0.00至0.03)与甲状腺功能减退发生风险降低相关,射频消融安全性SUCRA最高(99.86)。

关键数值与推荐

  • 结节再生长定义为热消融后结节体积增加>50%或剩余甲状腺组织出现新结节。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 长期数据匮乏。
  • 高质量随机对照试验匮乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Image-guided thermal ablation interventions are novel thermal-based modalities used for the treatment of benign thyroid nodules. Methods: We conducted a systematic review and a Bayesian network meta-analysis, examining studies using thermal ablation interventions in the treatment of benign nodular thyroid disease (PROSPERO CRD42022367680). The primary endpoints included volume reduction rate (VRR), and symptomatic score and cosmetic score improvement. Secondary endpoints included vocal disturbances, laryngeal nerve palsy, hypothyroidism, and nodular regrowth (defined by increased nodular volume of >50% for thermal ablation or new nodules arising in remaining thyroid tissue conventional surgery [CS]). Results: We included 16 studies (3 randomized controlled trials [RCTs] and 13 comparative case series), describing radiofrequency ablation (RFA), laser ablation (LA), microwave ablation (MWA), high-intensity focus ultrasound (HIFU), and CS, respectively. The review included data from 4112 patients followed for a mean of 11.9 months. Meta-analyses showed no significant differences among RFA, LA, MWA, HIFU, and CS regarding any of the primary endpoints of VRR, symptomatic score, and cosmetic score. In examining the surface under the cumulative ranking area (SUCRA) ranking, CS (SUCRA, 98.49), LA (SUCRA, 51.58), and MWA (SUCRA, 57.0) were identified as the three interventions that were most likely to result in the largest VRR, symptomatic and cosmetic score reduction. RFA, relative risk (RR) 0.19 [95% credibility interval (CI): 0.06 to 0.48], LA RR 0.23 [CI: 0.06 to 0.79], and MWA RR 0.25 [CI: 0.09 to 0.60] were associated with the greatest reduction in risk for postintervention vocal complications compared with CS, with RFA (SUCRA, 61.62) being ranked as the highest in safety. RFA RR 0.05 [CI: 0.00 to 0.40] and MWA RR 0.16 [CI: 0.02 to 0.73] were associated with a reduced risk of transient laryngeal nerve injury compared with CS. RFA RR 0.00 [CI: 0.00 to 0.00] and MWA RR 0.00 [CI: 0.00 to 0.03] were associated with a reduced risk of hypothyroidism occurrence compared with CS, with RFA (SUCRA, 99.86) yielding the highest safety ranking. RFA was associated with a reduced risk for nodular regrowth RR 0.09 [CI: 0.00 to 0.85], compared with CS. Conclusion: We have comprehensively reviewed the published literature on the efficacy and safety of thermal ablation modalities for benign thyroid nodules. Important research gaps remain regarding a paucity of both long-term data and high-quality RCTs.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Chorti A, Bontinis V, Tzikos G, et al. Minimally Invasive Treatments of Benign Thyroid Nodules: A Network Meta-Analysis of Short-Term Outcomes. Thyroid. 2023. PMID: 37166390. doi:10.1089/thy.2022.0671

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。